CPRIT makes childhood cancer a priority with 12% of its portfolio going to childhood cancer research — proportionately 3 times more than the national commitment. Ewing’s Sarcoma is a rare and devastating bone and soft-tissue cancer that mostly afflicts children and young adults for which no approved targeted therapies are currently available. Enter Salarius Pharmaceuticals, a clinical-stage oncology company and recipient of a 3-year $18.7 million CPRIT New Company Product Development award, who recently announced it enrolled the first patient in a Phase 1 clinical study targeting this cancer. David Arthur, Salarius CEO, rang the Nasdaq stock market opening bell July 30, 2019, to celebrate their recent milestone of becoming a publicly traded company. Mr. Arthur credited CPRIT for the company’s early success: “We wouldn’t be here today without the Cancer Prevention and Research Institute of Texas.”
Watch the video about this exciting story of a company coming to Texas to develop treatments for patients that need them the most.